Not 'simple' as we all know

I'm just curious why more of the big players in the industry, who the FDA is obviously watching close right now, don't try to play the process more.
You've already shown you're willing to spend the money on clinical trials and have published more than just about any company that isn't a subsidiary of a bigger foods company. It would be chump change compared to the cost of recalls/inventory destruction, no? A 50 person month long study ends up costing what, 200-300k depending on the university and the journal?
That said, and I'm not 110% positive on this, but I don't think SNS sells anything that isn't pre-1994, metabolite of pre-1994, non-chemically altered food constituent within the US currently.